IBA Business Update – First Quarter 2023
May 17 2023 - 1:00AM
IBA Business Update – First Quarter 2023
Louvain-la-Neuve, Belgium, 17 May
2023 - IBA (Ion Beam Applications S.A), the world leader
in particle accelerator technology, today announces its business
update for the first quarter ending 31 March 2023.
Group Overview
- Strong balance sheet maintained with EUR 103 million net cash
position
- Continued focus on delivering EUR 1.3 billion Group backlog,
with close to 65 equipment projects under installation in 2023
- Investment plan on track with R&D and digital initiatives
to ensure IBA maintains and further develops its world leading
technology offering
Olivier Legrain, Chief Executive Officer
of IBA commented: “IBA has made a solid start to the year
across all of our business units, with a continued focus on backlog
conversion, and we remain confident in positive momentum for IBA in
2023. Our pipeline is strong in Proton Therapy across all
geographies. In addition, we continue to see significant traction
within our Industrial Solutions business. Over the coming year IBA
will continue to focus on converting its record backlog, as well as
investing in future growth.”
Proton Therapy
- 32 projects ongoing, with seven Proteus®PLUS1 and 25
Proteus®ONE1 systems in progress
- Strong pipeline across all geographies, highlighting the
strength of the Proton Therapy market
- Proton therapy received further validation by ASTRO updating
its guidelines for which indications proton therapy is recommended,
expanding Group 12 indications
- Continued expansion of Campus, the world’s first online proton
therapy platform
Other Accelerators (RadioPharma,
Industrial)
- Four new machines sold in first quarter and one post-period
end
- Continued interest in X-ray and electron beam
sterilization
- A total of 18 installations ongoing in the first quarter, with
these expected to accelerate during the year
- Post-period end, IBA launched AKURACY®, an integrated solution
for cardiac PET imaging, at the European Association of
Cardiovascular Imaging (EACVI) meeting in May
Dosimetry
- Order intake of EUR 19.4 million, in line with Q1 2022
- Continuing to deliver on record backlog for Dosimetry
business
- A number of post-period updates:
- Launch of Dose-X, the next-generation reference class
electrometer, in April
- Launch of myQA® PROactive, the world’s first commercially
available risk management software for radiation oncology, in
May
- Distribution agreement signed for a combination of IBA’s myQA®
iON and ScandiDos’ Delta4 phantom+ offering
Outlook IBA has performed well
across all business units over the first quarter, with this
momentum expected to continue for the remainder of 2023 and beyond.
The pipeline remains strong and with a solid backlog, growing
services providing continuous revenues and a high cash position,
IBA remains confident in its positive outlook for the year ahead.
Despite the current geopolitical situation and economic
uncertainties IBA has clear visibility on its mid-term performance
and maintains its guidance as set out in its full year 2022
results.
***ENDS***
Financial calendar Half Year
Results
31 August 2023Business Update Q3
2022
16 November 2023
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,800 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More
information can be found at: www.iba-worldwide.com
For further information, please
contact:IBASoumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate Communication
Director+32 10 475 890communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Matthew Neal, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
1 Proteus®PLUS and Proteus®ONE are brand names of Proteus
235
2 Group 1 indications are those which frequently support the use
of proton therapy based on medical necessity and published clinical
data.
- 230517-IBA-Q1-Business-Update-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Apr 2023 to Apr 2024